HKSE · 2675.HK
Shenzhen Edge Medical Co Ltd
HK$30.70-HK$0.28 (-0.9%)
Shenzhen Edge Medical Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 58.34% below the high.
Loading market information…
HKSE · 1066.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Shandong Weigao Group Medical Polymer Company Limited’s quoted price sits in the lower half of its reported 52-week range, 44.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Shandong Weigao Group Medical Polymer Company Limited’s forward annual dividend is HK$0.20 per share, paid semi-annual. The forward yield is 6.2% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Shandong Weigao Group Medical Polymer Company Limited’s next earnings report is currently expected on Mar 30, 2027, with estimated earnings per share of HK$0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shandong Weigao Group Medical Polymer Company Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. The company structures its extensive operations into several core divisions, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other specialized segments. Its comprehensive product range covers a vast array of essential healthcare items. This includes devices for both vascular and non-vascular access, such as infusion sets, syringes, and specialized puncture needles, alongside various clinical collection kits. Shandong Weigao also provides solutions for wound care, offering sutures, healing dressings, cleaning products, and support devices for non-vascular catheters. In the realm of blood management, it supplies equipment for collection, storage, separation, and sterilization. The company is also a manufacturer of prefilled and pre-flush syringes, as well as instruments for blood collection and glucose monitoring. Its portfolio further extends to anesthesia consumables (general, local, and auxiliary), intensive care unit (ICU) equipment, and tools for both open and minimally invasive surgical procedures. Beyond disposables, the firm is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, and advanced medical components such as implantation materials and artificial organs. It also ventures into industrial manufacturing, producing medical-grade PVC granules, various plastic packaging materials, carton boxes, automated industrial equipment and parts, molds, and hemodialysis machines, encompassing Type I, Type II, and Type III medical devices. In addition to its manufacturing activities, Shandong Weigao offers a range of supporting services. These include finance leasing and factoring, wholesale distribution of Type I, surgical, and other disposable medical products. The company also provides asset management, enterprise consulting, management advisory, and comprehensive logistics and storage solutions, while actively exporting its products to international markets. Operating under recognized brands like Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, the company serves a diverse clientele that includes hospitals, blood banks, various other medical facilities, and a broad network of distributors.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 | Mar 26, 2024 | HK$0.20+5.88% vs estimate | HK$6.97B-58.74% vs estimate |
|---|
| Q2 2023 | Dec 31, 2023 | HK$0.20 | HK$7.01B |
|---|
| Q2 2023 | Aug 29, 2023 | HK$0.29-1.54% vs estimate | HK$7.46B-4.2% vs estimate |
|---|
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$30.70-HK$0.28 (-0.9%)
Shenzhen Edge Medical Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 58.34% below the high.
HK$1.47-HK$0.08 (-5.16%)
LifeTech Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 38.24% below the high.
HK$18.64-HK$0.58 (-3.02%)
Zylox-Tonbridge Medical Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.43% below the high.
HK$30.00+HK$0.36 (+1.21%)
Shanghai Kindly Medical Instruments Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.54% below the high.
HK$13.15-HK$1.10 (-7.72%)
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.59% below the high.
HK$3.74-HK$0.06 (-1.58%)
OrbusNeich Medical Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 23.31% below the high.
HK$6.22+HK$0.07 (+1.14%)
Medcaptain Medical Technology Co. Ltd. Class H’s quoted price sits in the lower half of its reported 52-week range, 42.94% below the high.
HK$3.77-HK$0.15 (-3.83%)
Peijia Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 48.85% below the high.
